Evidence map›Paper›PMID 37927339›Full record

ReviewFrontiers in aging neuroscience2023

Shared genetic architecture of COVID-19 and Alzheimer's disease.

Natalia Matveeva, Ivan Kiselev, Natalia Baulina, Ekaterina Semina, Viktor Kakotkin, Mikhail Agapov, Olga Kulakova, Olga Favorova

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Natalia MatveevaInstitute of Medicine and Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Ivan KiselevInstitute of Medicine and Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Natalia BaulinaInstitute of Medicine and Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Ekaterina SeminaInstitute of Medicine and Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Viktor KakotkinInstitute of Medicine and Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Mikhail AgapovInstitute of Medicine and Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Olga KulakovaInstitute of Medicine and Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Olga FavorovaInstitute of Medicine and Life Science, Immanuel Kant Baltic Federal University, Kaliningrad, Russia.
Immanuel Kant Baltic Federal University · RUPirogov Russian National Research Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) and the сoronavirus disease 2019 (COVID-19) have become a global health threat. At the height of the pandemic, major efforts were focused on reducing COVID-19-associated morbidity and mortality. Now is the time to study the long-term effects of the pandemic, particularly cognitive impairment associated with long COVID. In recent years much attention has been paid to the possible relationship between COVID-19 and Alzheimer's disease, which is considered a main cause of age-related cognitive impairment. Genetic predisposition was shown for both COVID-19 and Alzheimer's disease. However, the analysis of the similarity of the genetic architecture of these diseases is usually limited to indicating a positive genetic correlation between them. In this review, we have described intrinsic linkages between COVID-19 and Alzheimer's disease, pointed out shared susceptibility genes that were previously identified in genome-wide association studies of both COVID-19 and Alzheimer's disease, and highlighted a panel of SNPs that includes candidate genetic risk markers of the long COVID-associated cognitive impairment.

Indexed as

Alzheimer’s diseasecognitive impairmentCOVID-19genetic susceptibilityGWASlong Covidpathway analysisSNP

Identifiers

PMID37927339
PMCPMC10625425
OpenAlexW4387820738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.